### Medical Management (Cost Control) Trends

### A MILLIMAN GLOBAL FIRM



Milliman

Consultants and Actuaries

## **Topics**

- Definition
- Trends vs. cycles
- Options
- Influencers
- Limits

### Medical Management Cost Control Defined for This Presentation

### Benefit limits


- Cost sharing (CDHC, high deductible plans, tiered co-pays)
- Other coverage limitations/exclusions
- Utilization management
  - Medical necessity & contractual compliance review prior auth (PA), inpatient concurrent review (ICR), drug utilization review (DUR)
- Condition management
  - Case management (high cost, catastrophic, etc)
  - DM, population management
- Network management
  - PFP
  - Tiered, specialty and "closed" networks
  - Risk transfer (case rates, capitation, "shared" risk)
  - Quality\*\*\* (medical errors, etcs)

### Trends vs. Cycles

- Trends in cost control practices often are cyclical due to;
  - Demand (need) for savings
  - Program cost
  - Popularity
  - Politics
  - Sex appeal (such as having sparkles, being highly technical, producing lots of reports, has only positive impacts, costs a lot or maybe is a new cost)
- Some interventions produce one time savings but fail to alter underlying trends (for example, lower provider fee schedule)



Milliman




## **Increased Cost Sharing**

- CDHC (High Deductible Plans-HSAs – "Consumerism")
  - Growth from 2000 2004 100% per year (1,176,000)<sup>1</sup>
  - Wal-Mart, GM<sup>2</sup>, DaimlerChrysler<sup>3</sup>
  - 5.2% of total premium in 2005
  - 7 to 15% lower utilization

# The Story

 Specific utilization management (UM) processes, if done aggressively, can reduce claims cost

- Sherwood Report for BCBS Association
- Professional experience
- The trend is increasing number of Health Plans adopting the UM processes that reduce claims cost and performing these aggressively



# What is an Active and Aggressive UM Process

Process	Payment Denials <sup>1</sup> as % of Cases Reviewed
Inpatient Hospital Review	> 5 %
Precertification	> 5 to 10 %
Medical Necessity Review	Criteria/Guidelines used for most reviews
Steerage	Varies


•<sup>1</sup> Denials may include true avoidance of services

### What Works

Services	Process	Cost Impact	
All	Network Management, Provider Contracting	30% reduction	
Inpatient Hosp	PA & ICR	10% reduction	
Outpatient Procedures (OP Surgeries)	Prior Authorization	5% reduction	
High Cost Outpatient Diagnostic Tests	Prior Authorization	5% reduction	
Drugs	Drug Utilization Review	15% reduction	
Chronic Disease	Disease Management & Ambulatory Case Management	? 1% reduction	
Total		30% to 50% reduction	



Milliman




### Claims Cost Management What Doesn't Work

Service Area	Process	Cost Impact
		impaci
All	Ambulatory Case Management	0% reduction
All	Predictive modeling for future high cost individuals	0% reduction
	Total	0% reduction

### Inpatient Admission Review Typical Results

% of Admits Reviewed	50%
% of Admits Reviewed That Are Denied/ Diverted	5%
% of Denials Overturned on Appeal	9%
% of Admits Deferred Until Later	25%
Net Reduction	1.7% Reduction in Admissions



### Inpatient Continued Stay (LOS) Review Typical Results

% of Days Reviewed	80%
% of Days Reviewed That Are Denied/ Diverted	15%
% of Denials Overturned on Appeal	9%
Net Reduction	11%

An aggressive inpatient concurrent review program may downgrade an additional 10% of acute hospital days to a lower level of care (e.g., observation, skilled or subacute)

# WHAT ABOUT THE REST?

- Predictive modeling (for identification of high cost cases)
- Case management/Care coordination
- Population & Disease management



# **Predictive Modeling**

- Used to identify individuals to receive interventions
  - SOA study shows R2 (0.1 to 0.23) too low to accurately perform this task
  - Survey info (health risk assessments) being added to predictive models to improve effectiveness – to date no evidence showing improved results

## Case Management/Care Coordination

### What do we know?

- Probably effective only in very loosely managed indemnity programs, in most managed care programs unlikely to reduce costs beyond that achieved by UM
- At best, offers very small overall cost reduction
- Should be viewed as quality improvement function
- All reported cost savings are "soft" and are losing credibility


# Population & Disease Management

### What do we know?


- Does not include Service carve outs at core, most of these are UM programs and should be evaluated as such
- Demand management cost savings doubtful outside of staff model settings
- Disease or condition management programs
  - Popular, although now being critically scrutinized
  - Original contracts with DM vendors have flawed methodologies for calculating savings
  - Little but growing credible support for true cost savings
  - May be a replacement for non-effective UM programs


### Why Traditional Disease Management Doesn't Reduce Costs in US or Western Europe

- Treating elevated cholesterol to prevent heart attacks, strokes and cardiac death example; (US population based)
- For every avoided heart attack or stroke, about 100 people must receive a full years treatment with cholesterol lowering drug
- For every avoided cardiac death 500 people must receive a full years treatment with cholesterol lowering drug




### Cost Regression Due to Natural History of Disease





### Example of Regression to the Mean

Figure M-1 Medicare Diabetes Average Claim Cost



Quarters

## Health Plan Use of UM Processes

- Facts do not match perceptions or public statements
- Active and aggressive "Managed Care" processes as defined here actually have steadily increased over the past 10 years

### Prevalence of Active and Effective UM Processes

Process	Estimated % of Plans Using Process and Judged Aggressive
Inpatient Hospital Review	60 to 75 %
Precertification	5 to 10 %
Medical Necessity Review	50%
Steerage	5 %

()()

### Health Plan Use of Aggressive UM Processes (Mirkin Index)

Plan Type	1994	1999	2004
National	Rare	Few	Almost All*
Blues	None?	Few	Most
Regional for Profit	Few	Most	Half to Most
Regional not for Profit	None?	Few	Half to Most

## **Dave's Expert Opinions**

### Utilization Management

- Payment denial is primary tool
- Is "sentinel" effect still real probably not
- Case Management/Care Coordination
  - In our experience there is no good evidence these reduce costs

### • Other medical management functions/tools

 Unlikely to have any stand alone value to control costs - IT solutions are just coming to market, they may have value by reinforcing adherence to clinical guidelines and protocols or reducing the cost per review for UM

### Questions?

### A MILLIMAN GLOBAL FIRM



Milliman

Consultants and Actuaries